Paper Details

  1. Home
  2. Paper Details

Recent advances in synthetic pharmacotherapies for dyslipidaemias.

Author: CorsiniAlberto, GrecoMaria Francesca, RuscicaMassimiliano, SirtoriCesare R, WattsGerald F, YamashitaShizuya

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This review highlights the need for new oral agents targeting classical lipid targets. Pitavastatin, bempedoic acid, pemafibrate, eicosapentaenoic ethyl ester, gemcabene, anacetrapib, and probucol are promising options that address hypercholesterolemia and hypertriglyceridemia with good efficacy and potential safety.
Paper Details　
Original Abstract of the Article :
Despite the demonstrated benefits of statins and injectable biologics, there is a need for new and safe oral agents for addressing classical lipid targets, low-density lipoprotein cholesterol (LDL-C), triglycerides and high-density lipoprotein cholesterol (HDL-C). LDL-C is unquestionably causal in t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/2047487319845314

データ提供：米国国立医学図書館（NLM）

Synthetic Pharmacotherapies: A Desert Oasis for Dyslipidemia

The world of dyslipidemia, characterized by abnormal levels of lipids in the blood, is a complex and challenging one. This study explores the exciting field of synthetic pharmacotherapies for treating dyslipidemia, focusing on novel agents that target specific lipid pathways. The authors provide a comprehensive overview of recent advancements in this field, highlighting the emergence of new and potentially safer treatment options. Like skilled desert explorers seeking new sources of water, the authors meticulously investigated the potential of these novel agents, uncovering their ability to quench the thirst for better lipid management.

A New Oasis: Synthetic Pharmacotherapies for Dyslipidemia

The study reveals a promising landscape of new and innovative synthetic pharmacotherapies for dyslipidemia. The authors highlight the emergence of agents that target specific lipid pathways, offering a more targeted and potentially safer approach to lipid management. These novel agents, acting through diverse mechanisms, hold the promise of improving patient adherence and achieving optimal therapeutic goals. The study highlights the potential for these new drugs to significantly impact the treatment of dyslipidemia, offering hope for improved health outcomes and a reduced risk of cardiovascular events.

Dr. Camel's Conclusion

This research underscores the ongoing progress in the field of dyslipidemia management. The study's findings highlight the emergence of novel synthetic pharmacotherapies, offering a new and promising oasis in the desert of lipid management. These new agents, with their diverse mechanisms and potential for improved safety and efficacy, hold the promise of transforming the treatment of dyslipidemia and improving the health and well-being of individuals struggling with this common condition.

Date :
  1. Date Completed 2021-10-01
  2. Date Revised 2021-10-01
Further Info :

Pubmed ID

31060364

DOI: Digital Object Identifier

10.1177/2047487319845314

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.